Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100

Journal of Controlled Release

Volumn 143, Issue 1, 2010, Pages 151-158

  Li, Feng ^a   Lu, Yan ^a   Li, Wei ^a   Miller, Duane D ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer; MDR; Micelles; Microtubule destabilizer; Polymer

Indexed keywords

ANTICANCER ACTIVITIES; CASPASE-3; CELL APOPTOSIS; CELL LINES; CELL-CYCLE PROGRESSION; GROWTH OF CELLS; HEPG2 CELLS; IN-VITRO EVALUATION; MDR; MICROTUBULES; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; POLY (D ,L-LACTIDE);

CELL CULTURE; CELL DEATH; GLYCOPROTEINS; GROWTH KINETICS; MICELLES; ORGANIC POLYMERS; POLYETHYLENE GLYCOLS; SYNTHESIS (CHEMICAL);

WATER SUPPLY TUNNELS;

(2 PHENYL THIAZOL 4 YL) (3,4,5 TRIMETHOXYPHENYL)METHANONE; ANTINEOPLASTIC AGENT; CASPASE 3; COPOLYMER; GLYCOPROTEIN P; LUCIFERASE; POLYETHYLENE B POLYLACTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; GENES, REPORTER; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LACTATES; LIVER NEOPLASMS; LUCIFERASES; MALE; MICELLES; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; THIAZOLES; TUBULIN MODULATORS;

EID: 77950516980     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.12.028     Document Type: Article

References (28)

1. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4(4):253-265.
2. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48:353-374.
3. Jordan M.A., Kamath K. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 2007, 7(8):730-742.
4. Chu Q., Vincent M., Logan D., Mackay J.A., Evans W.K. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005, 50(3):355-374.
5. Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005, 6(4):229-239.
6. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
7. Seve P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol. 2008, 9(2):168-175.
8. Chen Z.S., Hopper-Borge E., Belinsky M.G., Shchaveleva I., Kotova E., Kruh G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 2003, 63(2):351-358.
9. Risinger A.L., Jackson E.M., Polin L.A., Helms G.L., LeBoeuf D.A., Joe P.A., Hopper-Borge E., Luduena R.F., Kruh G.D., Mooberry S.L. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008, 68(21):8881-8888.
10. Gradishar W. Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des. Devel. Ther. 2009, 3:163-171.
11. Lu Y., Li C.M., Wang Z., Ross C.R., Chen J., Dalton J.T., Li W., Miller D.D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 2009, 52(6):1701-1711.
12. Hennenfent K.L., Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann. Oncol. 2006, 17(5):735-749.
13. G. Gaucher, R.H. Marchessault, J.C. Leroux, Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes, J. Control Release (in press), http://doi:10.1016/j.jconrel.2009.11.012.
14. Danquah M., Li F., Duke C.B., Miller D.D., Mahato R.I. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm. Res. 2009, 26(9):2081-2092.
15. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71(3):409-419.
16. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 2000, 65(1-2):271-284.
17. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control Release 1998, 54(2):223-233.
18. Bronich T.K., Keifer P.A., Shlyakhtenko L.S., Kabanov A.V. Polymer micelle with cross-linked ionic core. J. Am. Chem. Soc 2005, 127(23):8236-8237.
19. Booser D.J., Esteva F.J., Rivera E., Valero V., Esparza-Guerra L., Priebe W., Hortobagyi G.N. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother. Pharmacol. 2002, 50(1):6-8.
20. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., Mumper R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69(9):3918-3926.
21. Hunt J.T. Discovery of ixabepilone. Mol. Cancer Ther. 2009, 8(2):275-281.
22. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007, 67(9):955-967.
23. Liu Y., Li Y., Wang H., Yu J., Lin H., Xu D., Wang Y., Liang A., Liang X., Zhang X., Fu M., Qian H., Lin C. BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer. Mol. Ther. 2009, 17(9):1509-1516.
24. Muckova K., Duffield J.S., Held K.D., Bonventre J.V., Sheridan A.M. cPLA2-interacting protein, PLIP, causes apoptosis and decreases G1 phase in mesangial cells. Am. J. Physiol. Renal. Physiol. 2006, 290(1):F70-79.
25. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88(11):2619-2628.
26. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., Rha S.Y., Lee M.Y., Ro J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108(2):241-250.
27. Marsac P.J., Shamblin S.L., Taylor L.S. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006, 23(10):2417-2426.
28. Latere Dwan'Isa J.P., Rouxhet L., Preat V., Brewster M.E., Arien A. Prediction of drug solubility in amphiphilic di-block copolymer micelles: the role of polymer-drug compatibility. Pharmazie 2007, 62(7):499-504.